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Three-dimensional structures of enzymes useful for b-lactam
antibiotic production
Thomas RM Barends, Hiromi Yoshida and Bauke W DijkstraSignificant advances have been made in the structure-based
engineering of enzymes useful for b-lactam antibiotic
production. Structure-based engineering of penicillin G acylase
and cephalosporin acylase has resulted in improved enzymes
for use in enzymatic production processes. The structures of
many other enzymes that could be used in the production
of b-lactam antibiotics, such as enzymes from the b-lactam
biosynthetic pathway and b-lactam antibiotic-converting
enzymes, have been determined. The interest in these
structures suggests that the future may see an even more
extensive use of rationally engineered biocatalysts in antibiotic
production than today.
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AbbreviationsACV dCurrent Opinio-(L-a-aminoadipoyl)-L-cysteinyl-D-valine7-ADCA 7-amino-deacetoxycephalosporanic acidAEH a-amino acid ester hydrolase6-APA 6-amino penicillanic acidCA cephalosporin acylaseCAH cephalosporin acetyl hydrolaseCPC cephalosporin CDAOCS deacetoxycephalosporin C synthaseDAOC/DACS deacetoxycephalosporin/deacetylcephalosporin C
synthaseGL-7-ACA glutaryl-7ACAIPNS isopenicillin N synthasePGA penicillin G acylaseIntroduction
Recent years have seen the elucidation of structures of
several enzymes that catalyze the biosynthesis and bio-
conversion of b-lactam antibiotics, in the anticipation that
structural information might help the rational engineering
of these enzymes towards effective biocatalysts for the
clean production of b-lactam antibiotics. In addition, the
structural information could be used to alter an antibiotic-n in Biotechnology 2004, 15:356–363producing enzyme in such a way that it produces b-lactam
antibiotics for which resistance is not (yet) an issue [1].
The b-lactam antibiotics can be described in terms of a b-
lactam nucleus with a sidechain (Figure 1). Many differ-
ent nuclei and sidechains are found in the antibiotics that
are in use today. For instance, the naturally occurring
penicillin G consists of the b-lactam nucleus 6-amino
penicillanic acid (6-APA) to which a phenylacetic acid
sidechain is coupled via an amide bond to the 6-amino
group of 6-APA. Different combinations of sidechains and
nuclei form antibiotics with distinctive properties; for
example, replacing the phenylacetic acid sidechain of
penicillin G with D-p-hydroxyphenylglycine results in
the b-lactam antibiotic amoxicillin, which in contrast to
penicillin G is orally stable. Likewise, the b-lactam
nucleus can be varied. Combining the D-p-hydroxyphe-
nylglycine sidechain of amoxicillin with the cephalos-
porin nucleus 7-amino-deacetoxycephalosporanic acid
(7-ADCA) gives the cephalosporin cephadroxil. The
numerous available sidechains and nuclei can thus be
used in a multitude of combinations, each resulting in
another b-lactam antibiotic.
Although the different sidechains are relatively easily
synthesized on an industrial scale by chemical means,
the chemical complexity of the b-lactam nucleus makes it
impossible to synthesize these molecules economically
in useful amounts. Instead, all b-lactam antibiotics pro-
duced today are derived from b-lactam nuclei obtained
from the fermentation of various microorganisms. For
example, the b-lactam antibiotic ampicillin is produced
from penicillin G obtained from the fermentation of
Penicillium chrysogenum: penicillin G is first hydrolyzed
enzymatically to give the b-lactam nucleus 6-APA, which
is then coupled to a D-phenylglycine sidechain to yield
ampicillin. This coupling, as well as the coupling to other
sidechains, can be done chemically, but enzymatic meth-
ods are being developed with the help of structural
research reviewed below (also see Figure 2). Similarly,
other nuclei — like those of the cephalosporins — can be
obtained from fermentative processes and enzymatic
cleavage of the sidechain.
Enzymes for sidechain conversions
Penicillin acylases are used in industry to catalyze the
hydrolysis of the naturally occurring penicillins G and V
to produce the b-lactam nucleus 6-APA, which is then
chemically converted into other antibiotics. Two differ-
ent enzymes — penicillin G acylase (PGA) and penicillinwww.sciencedirect.com
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b-Lactam antibiotics comprise a b-lactam nucleus coupled to a
sidechain. Examples of two penicillins (a) penicillin G and (b) amoxicillin
and (c) a cephalosporin, cephadroxil.V acylase (PVA) — are currently used, of which PGA from
Escherichia coli is the most important. Together, these
enzymes are responsible for the production of thousands
of tons of 6-APA annually [2].
PGA (Figure 3) is a member of the Ntn hydrolase family,
members of which share a typical fold of a double layer of
b sheets, sandwiched between a helices. The enzymes
are produced as proenzymes, which are self-activated by
the autocatalytic cleavage of the polypeptide resulting in
an a and a b chain. The resulting N-terminal residue of
the b-chain is always a serine, threonine or cysteine which
acts as the nucleophile in both the maturation reaction
and the hydrolysis of the substrate [3]. The nucleophi-
licity of the hydroxyl or thiol group of this residue is
enhanced through general base catalysis by its own
N-terminal amino moiety.
In the PGA-catalyzed hydrolysis of penicillin G
(Figure 2a), the nucleophilic serine attacks the carbonyl
carbon atom of the amide bond between the phenylacetic
acid sidechain and the 6-APA nucleus, liberating 6-APA
and forming an acyl enzyme. The acyl enzyme is then
hydrolyzed, resulting in phenylacetic acid and a regen-
erated active site. The specificity of PGA for the pheny-
lacetyl sidechain, and the localization of its gene close to
genes encoding enzymes involved in p-hydroxyphenyla-
cetic acid degradation, suggest that in vivo the enzymewww.sciencedirect.comprovides a means for the conversion of phenylacetylated
compounds [4]. Three-dimensional structures of the
enzyme show a clear binding pocket for a phenylacetyl
group, but the enzyme can bind other compounds too,
responding through conformational changes involving
sidechain motions, notably of aArg145 and aPhe146 [4].
PGA can also be used for the coupling of sidechains to an
amino-b-lactam. To this end, the enzyme is acylated by
an ester or amide of the desired acyl sidechain and the
resulting acyl enzyme is ‘aminolysed’ by an amino-b-
lactam, resulting in a semisynthetic antibiotic. As the acyl
enzyme can also react with a water molecule and be
hydrolyzed, and because the antibiotic product may also
be hydrolyzed by the enzyme, ways are being sought to
diminish these undesired hydrolytic side reactions and
so to increase the yield [5].
The rational design of PGA mutants with such increased
production levels requires knowledge of the way in which
amino-b-lactams and the antibiotic products bind to the
acyl enzyme. Unfortunately, a clearly defined binding
pocket for the b-lactam nucleus cannot be distinguished
in the crystal structure of wild-type PGA. However,
crystal structures of an inactive PGA mutant in complex
with penicillin G (Protein Data Bank [PDB] codes 1FXV
[5] and 1GM7 [6]) and of the wild-type PGA in complex
with the slowly hydrolyzed penicillin G sulfoxide (PDB
code 1GM9 [6]) have been determined and resulted in
several residues being implicated in penicillin binding.
Mutagenesis of active-site residues resulted in mutant
PGAs with an increased propensity to catalyze antibiotic
synthesis rather than the hydrolytic side reactions [5,7,8].
This research also led to the design of three mutants
(aPhe146Tyr, bPhe24Ala and aPhe146Tyr/bPhe24Ala)
that have increased affinities for Ca-substituted pheny-
lacetic acid derivatives, making them interesting for
the coupling of such compounds to b-lactams. Crystal
structures suggested that van der Waals interactions
with the phenyl hydroxyl group introduced by the
aPhe146Tyr mutation explain the increased affinity for
a-substituents on the substrate (WBL Alkema et al.,
unpublished).
Acyl coenzyme A: isopenicillin N acyltransferase (AT) is
found in the biosynthetic route towards penicillin G,
where it catalyzes the exchange of the a-amino adipic
acid sidechain of isopenicillin N for phenylacetic acid,
resulting in penicillin G (Figure 2b). As this enzyme
accepts a wide variety of sidechains, it might become a
very useful tool in antibiotic production and structural
studies are under way [9].
Cephalosporin acylase (CA; also called glutaryl acylase)
can be used in enzymatic production methods for semi-
synthetic cephalosporins. Starting from fermented cepha-
losporin C (CPC), the cephalosporin nucleus 7-amino
cephalosporanic acid (7-ACA) is commonly obtainedCurrent Opinion in Biotechnology 2004, 15:356–363
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Reactions catalyzed by the enzymes reviewed in the text. (a) Penicillin G hydrolysis by penicillin G acylase (PGA). (b) Isopenicillin N conversion to
penicillin G by acyl-coenzyme A: isopenicillin N acyltransferase (AT). (c) Glutaryl 7-ACA hydrolysis catalyzed by cephalosporin acylase (CA).
(d) Acylation of 6-APA with phenylglycine methylester catalyzed by a-amino acid ester hydrolase (AEH). (e) Formation of isopenicillin N from the
tripeptide ACV by isopenicillin N synthase (IPNS). (f) Ring expansion of isopenicillin N into deacetoxycephalosporin C by deacetoxycephalosporin
C synthase (DAOCS). (g) Hydroxylation of deacetoxycephalosporin C by deacetoxycephalosporin/deacetylcephalosporin C synthase
(DAOC/DACS). (h) Deacetylation of cephalosporin C by cephalosporin acetyl hydrolase (CAH).
Current Opinion in Biotechnology 2004, 15:356–363 www.sciencedirect.com
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Figure 3
The fold of Escherichia coli penicillin acylase. This figure was
prepared from the coordinates of the inactive mutant complexed with
penicillin [5]. Penicillin is shown in ball-and-stick representation.
(Figure drawn with Molscript [27].)using hazardous, noxious chemicals. A more environ-
mentally friendly alternative is offered by enzymatic
hydrolysis using CA. However, the catalytic activity of
CA on CPC is quite low compared to its activity on theFigure 4
The crystal structure of Pseudomonas diminuta cephalosporin acylase
[11]. (Figure drawn with Molscript [27].)
www.sciencedirect.comnatural substrate glutaryl-7ACA (GL-7-ACA) shown in
Figure 2c. Therefore, the enzyme is being engineered to
increase its activity on CPC [10].
Kim and colleagues determined the crystal structures of
both the inactive precursor and the active, mature CA
of Pseudomonas diminuta (PDB codes 1KEH and 1FM2
[11,12]; Figure 4) The core of the enzyme showed an Ntn
hydrolase fold, and the active site was found to be similar
to that of penicillin acylase, although CA and PGA show a
very different structure away from the active site [12].
Structures of CA with bound GL-7ACA and glutarate
(PDB codes 1JBZ and 1JWO, respectively) identified the
residues that are important for substrate binding
(aTyr149, aArg155, bLeu24, bTyr33, bGln50, bArg57,
bPhe177, bVal70, bSer1 and aSer152 [10]). In both
complexes, the glutaryl sidechain is buried inside a deep
pocket, and the observed interactions in the active site
suggest an explanation for the enzyme’s preference for
GL-7-ACA over CPC. Because the D-a-aminoadipyl side-
chain of CPC is larger than the glutaryl sidechain in GL-7-
ACA, it would collide with the binding site residues.
Therefore, Kim and Hol [10] proposed to mutate bulky
residues in the binding site to smaller ones to increase the
activity on CPC. From structures of CA with bound
phosphate and ethylene glycol and with bound glycerol,
Fritz-Wolf et al. [13] also proposed mutations that should
allow CA to act more efficiently on CPC. Site-directed
mutagenesis based on the substrate-binding mode
observed by Kim and Hol [10] eventually resulted in a
triple mutant (bGln50Met/aTyr149Lys/bPhe177Gly)
that exhibited drastically increased deacylation activity
on CPC — up to 790% that of the wild type [14].
Enzyme structures may also aid the understanding of
directed evolution studies. Otten et al. [15] have evolved
Pseudomonas SY-77 CA into a more efficient adipyl acylase
for the conversion of adipyl-7-ADCA into the free cepha-
losporin nucleus 7-ADCA by the selection of clones from
a library of mutants. The best enzymes showed mutations
in positions close to the substrate-binding site. Strikingly,
in this study, residue Asn266 was implicated in the
substrate specificity for the first time, and the Asn266His
mutant showed increased activity on both glutaryl- and
adipyl-7-ADCA. A model based on the crystal structure of
the CA enzyme in complex with glutaryl-7-ACA sug-
gested that Arg255 is responsible for the binding of the
glutaryl sidechain’s carboxylate group. The Arg255 side-
chain is kept in the correct position for this interaction by
hydrogen bonds involving Asn266. Mutating Asn266 was
proposed to perturb these interactions and thus alter the
substrate selectivity.
Like penicillin acylases, the a-amino acid ester hydro-
lases or AEHs are capable of catalyzing the removal and
attachment of the sidechain of b-lactam antibiotics.
Importantly, however, the AEHs have a very strongCurrent Opinion in Biotechnology 2004, 15:356–363
360 Protein technologies and commercial enzymespreference for substrates with an a-amino group on the
acyl chain. Thus, they can be used to synthesize impor-
tant antibiotics like ampicillin, amoxicillin, cephalexin
and cephadroxil, which have either a D-phenylglycine or a
p-hydroxy-D-phenylglycine sidechain. As an example,
Figure 2d shows the AEH-catalyzed synthesis of ampi-
cillin.
Unlike PGA, the AEHs are not inhibited by phenylacetic
acid and can therefore be very useful in a one-pot trans-
acylation scheme [16], in which a natural antibiotic, an
ester (or amide) of the desired new a-amino acyl chain, a
PGA and an AEH are present at the same time. The PGA
can catalyze the deacylation of penicillin G, while the
AEH acylates the resulting 6-APA by reaction with the
new acyl donor. Although the first AEHs were purified in
the 1980s, the first AEH genes were cloned only in the
past few years [17,18] so that rational engineering has only
recently become a possibility.Figure 5
The fold of Xanthomonas citri AEH [18]. The different domains are
individually shaded: the a/b-hydrolase fold domain is in light gray; the
jellyroll fold domain in medium gray; and the cap domain in dark gray.
The residues of the catalytic triad are indicated in ball-and-stick
representation. (Figure drawn with Molscript [27].)
Current Opinion in Biotechnology 2004, 15:356–363Sequence alignments, mutational analyses and labeling
experiments suggested that the AEHs are a/b-hydrolase
fold enzymes employing a classical Ser-His-Asp catalytic
triad [17,19]. This was subsequently confirmed by the
crystal structure of the Xanthomonas citri AEH [18] (PDB
code 1MPX). The structure (Figure 5) showed a three-
domain fold including an a/b-hydrolase domain, a pre-
dominantly helical cap domain and a domain with a
jellyroll fold. The active site is found at the interface
of the three domains, with the catalytic triad residues
Ser174, His340 and Asp307 located in their canonical
positions in the a/b-hydrolase domain. A putative binding
pocket for the acyl chain is formed by residues from the a/
b-hydrolase and cap domains. Strikingly, a cluster of three
acidic residues (Glu309, Asp310 and Asp208) protrudes
into this pocket forming a well-defined interaction site for
the substrate’s amino group, explaining the substrate
specificity. As with PGA, however, the native structure
showed no clear binding site for a b-lactam acyl acceptor.
Modeling tentatively suggests the involvement of Tyr82,
which is also involved in catalysis, as one of the oxyanion-
stabilizing residues.
Structural studies on AEHs could, as was the case for
PGA, help the design of mutants with improved bioca-
talytic properties or even of mutants able to accept
completely new sidechains for the production of new
antibiotics. To this end, residues on the cap domain, like
Trp209, Tyr222 and Asn219, which seem to be involved
in recognition of the acyl chain, may be mutated. Alter-
natively, the carboxylate cluster may be altered with a
view to drastically changing the enzyme’s specificity
Enzymes for b-lactam nucleus formation
Isopenicillin N synthase (IPNS) [20] and deacetoxyce-
phalosporin C synthase (DAOCS) [21] are enzymes
involved in the biosynthesis of the b-lactam nucleus that
are structurally well characterized. In a review in 2001,
Andersson et al. [1] proposed that such enzymes could be
modified to accept new substrates, allowing the formation
of intermediates that are more easily used in subsequent
steps of production processes or even enabling the direct
formation of compounds that do not require any addi-
tional conversions but are immediately ready for use as a
drug.
IPNS and DAOCS share a common structural scaffold
with a central jellyroll fold surrounded by a helices
(Figures 6 and 7) and both use a catalytic mechanism
based on a ferrous iron atom [1]. IPNS occurs in the
biosynthetic route for penicillin G formation where, with-
out assistance, it synthesizes the entire intricate two-ring
b-lactam structure of the penicillin precursor isopenicillin
N from the tripeptide d-(L-a-aminoadipoyl)-L-cysteinyl-
D-valine (ACV). This process is an oxidative reaction
fueled by molecular oxygen (Figure 2e). Working under
anaerobic conditions to stop the enzyme in its tracks,www.sciencedirect.com
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Figure 7
Fold of DAOCS [21]. The catalytic iron atom is shown as a sphere.
(Figure drawn with Molscript [27].)
Figure 6
The structure of IPNS [20]. The catalytic iron atom is shown as a sphere.
(Figure drawn with Molscript [27].)Roach et al. [20] have obtained the crystal structures of
IPNS in complex with ACV and iron and of IPNS in
complex with iron, ACV and nitric oxide, which is a non-
reactive analog of oxygen. The high resolution of their
diffraction data (1.3 A˚ and 1.45 A˚, respectively; PDB
codes 1BK0 and 1BLZ) allowed a detailed view of the
active site. This showed a square-pyramidal coordination
of the iron with the cysteinyl-derived sulfur atom of ACV
coordinating the iron apically. Nitric oxide binds laterally,
in a nonlinear way (i.e. with an obtuse angle between Fe,
N and O), which allowed the proposal of a reaction
mechanism. If oxygen also binds in such a nonlinear
way, it would be perfectly placed to abstract two hydrogen
atoms from ACV, resulting in b-lactam ring closure and
the formation of one water molecule from one of the
oxygen atoms on the iron. The remaining oxygen could
then abstract a hydrogen atom from the valine sidechain
of ACV, inducing attack on the sulfur atom and formation
of the second (thiazolidine) ring. A later structural study
[22] (PDB codes 1QJF, 1QIQ and 1QJE) supported this
sequence of events by trapping a monocyclic intermedi-
ate in the crystal using a specially selected ligand that did
convert into a monocylic b-lactam, but which did not form
the thiazolidine ring. Long et al. [23] have reported
structures of IPNS in complex with a truncated substrate
(PDB codes 1OC1 and 1OBN), which is converted into
three different products. Combining these structures withwww.sciencedirect.commodeling studies, they investigated the product selectiv-
ity of IPNS acting on substrates other than ACV. This
may provide useful information for the engineering of
IPNS for the development of new synthetic procedures.
The bacterial enzyme DAOCS catalyzes a ring expansion,
turning the five-membered thiazolidine ring of a peni-
cillin nucleus into the six-membered dihydrothiazine ring
of a cephalosporin (Figure 2f), and has a central role in the
biosynthesis of cephalosporins by prokaryotes [21]. This
ring expansion is also an oxidative process requiring
molecular oxygen but, in contrast to IPNS, DAOCS also
requires 2-oxoglutarate, which is used in the oxidative
half reaction needed to generate the iron (IV) center. In
this half reaction, the oxoacid is decarboxylated to gen-
erate carbon dioxide and succinate.
The structures of DAOCS from Streptomyces clavuligerus
alone and with bound 2-oxoglutarate were solved by
Valega˚rd et al. [21] (PDB codes 1RXF and 1RXG).
Recently, Valega˚rd et al. [24] have explained how the
extremely unstable iron (IV) in DAOCS is kept in check
until its reactivity is required. By elucidating several
crystal structures of enzyme–substrate and enzyme–pro-
duct complexes (PDB codes 1UO9, 1UOF, 1UOB, 1UNB
and 1UOG), they show that the binding sites for the 2-
oxoacid and the b-lactam overlap. They propose that afterCurrent Opinion in Biotechnology 2004, 15:356–363
362 Protein technologies and commercial enzymesthe generation of the iron (IV) species through oxidation
by oxygen and carbon dioxide expulsion from the 2-
oxoglutarate, the succinate product remains bound to
the iron and stabilizes its charge. The penicillin substrate,
competing for the same binding site, displaces the succi-
nate and in doing so causes oxidative attack on itself by the
iron, which the authors refer to as being ‘booby-trapped’ in
this way. The paper by Valega˚rd et al. continues to propose
a detailed reaction mechanism for ring expansion in which
the iron (IV) binds the sulfur atom of the thiazolidine ring.
An oxygen atom bound to the iron abstracts a hydrogen
atom from one of the thiazolidine ring’s methyl groups,
generating a radical on this methyl group. This then
attacks the sulfur atom, resulting in its inclusion in the
ring and deacetoxycephalosporin C formation.
Thus, crystal structures have served to elucidate the
mechanism of b-lactam biosynthesis. Moreover, the
resulting structures show the precise interactions
between b-lactam-forming and b-lactam-converting
enzymes and their substrates, which makes rational engi-
neering a possibility.
Two other enzymes, DACS and DAOC/DACS, are also
involved in cephalosporin biosynthesis. DACS hydroxy-
lates deacetoxycephems, whereas DAOC/DACS shows
both DACS and DAOCS activity (Figure 2f,g). Although
no structures are available of either DACS or DAOC/
DACS, the structural information on DAOCS can be
extrapolated to these enzymes. Recently, Lloyd et al.Figure 8
Fold of a monomer of the hexameric cephalosporin deacetylase from
Bacillus subtilis [26]. (Figure drawn with Molscript [27].)
Current Opinion in Biotechnology 2004, 15:356–363[25] have used homology modeling of DAOC/DACS
and DACS based on the S. clavuligerus DAOCS structure
to identify important residues in DAOC/DACS from
Cephalosporium acremonium, which shows 57% sequence
identity to the Streptomyces DAOCS. It was shown that
single amino acid replacements could strongly increase
one of the activities of DAOC/DACS relative to the other,
but the molecular details of this remarkable success
remain to be elucidated.
A completely different class of enzymes, the so-called
cephalosporin acetyl hydrolases, might also be of use in
the enzymatic production of antibiotics. Vincent et al. [26]
have reported the structure (Figure 8) of cephalosporin
acetyl hydrolase (CAH) from Bacillus subtilis 168 (PDB
code 1ODS), which can remove the acetyl group from the
C10 position on the cephalosporin C nucleus (Figure 2h).
This enzyme is an a/b-hydrolase with a Ser-His-Asp
catalytic triad. It might be possible in the future to
engineer the structure of this enzyme to enable the
(de)acylation of cephalosporins on the C10 position with
various acyl chains, which may open up a route to new
antibiotics [26].
Conclusions
A large number of enzymes is being investigated with a
view to engineering them for use in the industrial pro-
duction of b-lactam antibiotics. Given this interest, in the
near future enzymatic semisynthesis may replace chemi-
cal methods for antibiotic production, playing an even
greater role in their manufacture than at present. Struc-
tural research has contributed much to this ongoing
development by yielding the structures of enzymes use-
ful for both sidechain and b-lactam nucleus conversions.
The examples of penicillin G acylase and cephalosporin
acylase, for which several mutants with improved proper-
ties have already been prepared with the aid of structural
research, hold promise for the engineering of the other
enzymes reviewed in this paper.
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